Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. biotechnology engineering
Show results for
Products
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Biotechnology Engineering Articles & Analysis

12 news found

Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

This special offer is valid through December 4, 2024, at 23:59 EST.Our monodispersed PEGs are highly versatile and indispensable in various pharmaceutical and biotechnological applications. These precision-engineered compounds are widely used in PEGylation, a process that enhances the pharmacokinetics and stability of therapeutic molecules. ...

ByBiopharma PEG Scientific Inc


Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Recombinant indicates that this enzyme is produced using advanced biotechnological methods, specifically genetic engineering. This method ensures fidelity and reproducibility of the enzyme, which are essential for consistent research results and large-scale applications. ...

ByCreative Enzymes


Multi-protein Expression Service in Insect Cells Now Available at Profacgen

Multi-protein Expression Service in Insect Cells Now Available at Profacgen

Profacgen, one of the leading biotechnology companies that provides first-class protein expression services, recently announced the release of multi-protein expression service in insect cells, to help scientists conduct protein co-expression network analysis and interaction studies. ...

ByProfacgen


Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022

Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. ...

ByObsidian Therapeutics, Inc.


Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. ...

ByObsidian Therapeutics, Inc.


Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform at the American Associate of Cancer Research (AACR) Annual Meeting 2022

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present data highlighting the potential of the company’s cytoDRiVE® platform technology, which allows regulation of protein expression using small molecule drugs. ...

ByObsidian Therapeutics, Inc.


Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. ...

ByAlkermes


Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). ...

ByObsidian Therapeutics, Inc.


Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021

Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021

Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology (ESMO) Congress, which will be hosted virtually September 16-21, 2021. ...

ByObsidian Therapeutics, Inc.


Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting

Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting

Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. ...

ByObsidian Therapeutics, Inc.


Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing

About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. The Company expects to submit an IND in mid-2022 for its lead cytoTIL™ program, a novel engineered tumor infiltrating lymphocyte therapy ...

ByObsidian Therapeutics, Inc.


Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians

Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians

Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat doctors is pleased to announce the closing of a $1.5 million funding round. The company has raised over $2 million from private investors since 2018. The additional funds will be used to produce inventory and ramp up sales & marketing to support the rollout of the company’s first patented ...

ByDalent Medical

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT